Emerging drugs for obesity: Linking novel biological mechanisms to pharmaceutical pipelines

Expert Opinion on Emerging Drugs

Volumn 10, Issue 3, 2005, Pages 643-660

  Correia, Marcelo L G ^a   Haynes, William G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Antiobesity drugs; Appetite regulation; Central nervous system; Energy homeostasis; Obesity

Indexed keywords

4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; A 71378; A 74498; AC 162352; ANTIOBESITY AGENT; AR R 1589; BMS 192548; CBT 001452; CHIR 01020; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CP 945598; EXENDIN 4; FPL 14294; FR 79620; GI 181771; IDDB 41331; LANICEMINE; LEPTIN; LIRAGLUTIDE; MELANIN CONCENTRATING HORMONE; N (6 DIMETHYLAMINOMETHYL 5,6,7,8 TETRAHYDRO 2 NAPHTHYL) 4' FLUORO 1,1' BIPHENYL 4 CARBOXAMIDE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NEUROPEPTIDE Y; PD 160170; PEGAXOKINE; PEPTIDE YY; PRAMLINTIDE; PT 15; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RIMONABANT; RO 27 3225; SNAP 7941; UNCLASSIFIED DRUG;

BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG TOLERABILITY; DYSLIPIDEMIA; ENERGY METABOLISM; HUMAN; HYPERTENSION; LIFESTYLE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PIPELINE; REVIEW; UNITED STATES;

ANTI-OBESITY AGENTS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; OBESITY;

EID: 23844495824     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.10.3.643     Document Type: Review

References (82)

1. FAGOT-CAMPAGNA A: Emergence of Type 2 diabetes mellitus in children: epidemiological evidence. J. Pediatr. Endocrinol. Metab. (2000) 13(Suppl 6):1395-1402.
2. NATIONAL HEART, LUNG AND BLOOD INSTITITUTE AND NATIONAL INSTITUTES OF HEALTH: In: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults: The Evidence Report, NIH Publication No. 98-4083. (1998):23. Comprehensive guidelines covering the diagnosis, evaluation and management of obesity.
3. FINKELSTEIN EA, FIEBELKORN IC, WANG G: National medical spending attributable to overweight and obesity: how much, and who's paying? Health Affairs (2003) W3:219-226.
4. OSTER G, THOMPSON D, EDELSBERG J, BIRD AP, COLDITZ GA: Lifetime health and economic benefits of weight loss among obese persons. Am. J. Public Health (1999) 89(10):1536-1542.
5. OLSON MB, KELSEY SF, BITTNER V et al.: Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: a report from the NHLBI-sponsored WISE study. Women's Ischemia Syndrome Evaluation Study Group. J. Am. Coll. Cardiol. (2000) 36(5):1565-1571.
6. SCHULZ M, LIESE AD, BOEING H, CUNNINGHAM JE, MOORE CG, KROKE A: Associations of short-term weight changes and weight cycling with incidence of essential hypertension in the EPIC-Potsdam Study. J. Hum. Hypertens. (2005) 19(1):61-67.
7. MOKDAD AH, FORD ES, BOWMAN BA et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA (2003) 289(1):76-79.
8. STEINBROOK R: Surgery for severe obesity. N. Engl. J. Med. (2004) 350(11):1075-1079.
9. BUCHWALD H, WILLIAMS SE: Bariatric surgery worldwide 2003. Obes. Surg. (2004) 14(9):1157-1164.
10. CUMMINGS DE, WEIGLE DS, FRAYO RS et al.: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. (2002) 346(21):1623-1630.
11. NATIONAL HEART, LUNG AND BLOOD INSTITITUTE AND NATIONAL INSTITUTES OF HEALTH: In: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH Publication No. 98-4083. (1998):53. Comprehensive guidelines covering the diagnosis, evaluation and management of obesity.
12. HAYNES WG, MARK AL: Pharmacotherapy of obesity: lessons from clinical trials in hypertension. J. Hypertens. (2002) 20:1731-1735. Interesting conceptual discussion about antiobesity treatment.
13. HALFORD JC: Clinical pharmacotherapy for obesity: current drugs and those in advanced development. Curr. Drug Targets (2004) 5(7):637-646.
14. RUOF J, GOLAY A, BERNE C, COLLIN C, LENTZ J, MAETZEL A: Orlistat in responding obese Type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int. J. Obes. Relat. Metab. Disord. (2005) 29(5):517-523.
15. WARREN E, BRENNAN A, AKEHURST R: Cost-effectiveness of sibutramine in the treatment of obesity. Med. Decis. Making (2004) 24(1):9-19.
16. RAHMOUNI K, HAYNES W: Leptin and the central neural mechanisms of obesity hypertension. Drugs Today (2002) 38(12):807-817.
17. MORTON GJ, BELVINS JE, WILLIAMS DL et al.: Leptin action in the forebrain regulates the hindbrain response to satiety signals. J. Clin. Invest. (2005) 15:703-710.
18. SATOH N, OGAWA Y, KATSUURA G et al.: The arcuate nucleus as a primary site of satiety effect of leptin in rats. Neurosci. Lett. (1997) 224(3):149-152.
19. SCHWARTZ MW, SEELEY RJ, CAMPFIELD LA, BURN P, BASKIN DG: Identification of targets of leptin action in rat hypothalamus. J. Clin. Invest. (1996) 98(5):1101-1106.
20. WILDING JP, GILBEY SG, BAILEY CJ et al.: Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology (1993) 132(5):1939-1944.
21. ERICKSON JC, HOLLOPETER G, PALMITER RD: Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science (1996) 274(5293):1704-1707.
22. HOLLOPETER G, ERICKSON JC, SEELEY RJ, MARSH DJ, PALMITER RD: Response of neuropeptide Y-deficient mice to feeding effectors. Regul. Pept. (1998) 75-76:383-389.
23. MARSH DJ, HOLLOPETER G, KAFER KE, PALMITER RD: Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat. Med. (1998) 4(6):718-721.
24. BATTERHAM RL, COWLEY MA, SMALL CJ et al.: Gut hormone PYY(3-36) physiologically inhibits food intake. Nature (2002) 418(6898):650-654.
25. WYNNE K, STANLEY S, MCGOWAN B, BLOOM S: Appetite control. J. Endocrinol. (2005) 184(2):291-318. Comprehensive review of mechanisms involved in appetite and metabolism control.
26. CHALLIS BG, COLL AP, YEO GS et al.: Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc. Natl. Acad. Sci. USA (2004) 101:4695-4700.
27. HALATCHEV IG, ELLACOTT KL, FAN W, CONE RD: Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology (2004) 145(6):2585-2590.
28. BENOIT SC, TSCHOP MH: PYY3-36 "monkeys around" with energy balance. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 288(2):R358-R359.
29. KANATANI A, MASHIKO S, MURAI N et al.: Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology (2000) 141(3):1011-1016.
30. SWART I, JAHNG JW, OVERTON JM, HOUPT TA: Hypothalamic NPY, AGRP, and POMC mRNA responses to leptin and refeeding in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2002) 283(5):R1020-R1026.
31. BALTHASAR N, COPPARI R, MCMINN J et al.: Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron (2004) 42(6):983-991.
32. BENOIT SC, SCHWARTZ MW, LACHEY JL et al.: A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J. Neurosci. (2000) 20(9):3442-3448.
33. HUSZAR D, LYNCH CA, FAIRCHILD-HUNTRESS V et al.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell (1997) 88(1):131-141.
34. FAROOQI IS, YEO GS, KEOGH JM et al.: Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J. Clin. Invest. (2000) 106(2):271-279.
35. SEELEY RJ, YAGALOFF KA, FISHER SL et al.: Melanocortin receptors in leptin effects. Nature (1997) 390(6658):349.
36. HAYNES WG, MORGAN DA, DJALALI A, SIVITZ WI, MARK AL: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension (1999) 33(1 Pt 2):542-547.
37. SMALL CJ, LIU YL, STANLEY SA et al.: Chronic CNS administration of agouti-related protein (Agrp) reduces energy expenditure. Int. J. Obes. Relat. Metab. Disord. (2003) 27(4):530-533.
38. OLLMANN MM, WILSON BD, YANG YK et al.: Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science (1997) 278(5335):135-138.
39. (Erratum in: Science [1998]281[5383]:1615)
40. BREEN TL, CONWELL IM, WARDLAW SL: Effects of fasting, leptin, and insulin on AGRP and POMC peptide release in the hypothalamus. Brain Res. (2005) 1032(1-2):141-148.
41. WILSON BD, BAGNOL D, KAELIN CB et al.: Physiological and anatomical circuitry between agouti-related protein and leptin signaling. Endocrinology (1999) 140(5):2387-2397.
42. DHILLO WS, SMALL CJ, STANLEY SA et al.: Hypothalamic interactions between neuropeptide Y, agouti-related protein, cocaine- and amphetamine-regulated transcript and alpha-melanocyte-stimulating hormone in vitro in male rats. J. Neuroendocrinol. (2002) 14(9):725-730.
43. KRISTENSEN P, JUDGE ME, THIM L et al.: Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature (1998) 393(6680):72-76.
44. ELLIOTT JC, HARROLD JA, BRODIN P et al.: Increases in melanin-concentrating hormone and MCH receptor levels in the hypothalamus of dietary-obese rats. Mol. Brain Res. (2004) 128(2):150-159.
45. SHEARMAN LP, CAMACHO RE, SLOAN S et al.: Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. Eur. J. Pharmacol. (2003) 475(1-3):37-47.
46. GAVRILA A, CHAN JL, MILLER LC, HEIST K, YIANNAKOURIS N, MANTZOROS CS: Circulating melanin-concentrating hormone, agouti-related protein, and {alpha}-melanocyte-stimulating hormone levels in relation to body composition: alterations in response to food deprivation and recombinant human leptin administration. J. Clin. Endocrinol. Metab. (2005) 90(2):1047-1054.
47. KAWANO H, HONMA S, HONMA A, HORIE M, KAWANO Y, HAYASHI S: Melanin-concentrating hormone neuron system: the wide web that controls the feeding. Anat. Sci. Int. (2002) 77(3):149-160.
48. DI MARZO V, GOPARAJU SK, WANG L et al.: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 410(6830):822-825.
49. VERTY AN, MCFARLANE JR, MCGREGOR IS, MALLET PE: Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology (2004) 145(7):3224-3231.
50. ASIN KE, GORE PA Jr, BEDNARZ L, HOLLADAY M, NADZAN AM: Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats. Brain Res. (1992) 571(1):169-174.
51. MORAN TH, BALDESSARINI AR, SALORIO CF, LOWERY T, SCHWARTZ GJ: Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am. J. Physiol. (1997) 272(4 Pt 2):R1245-R1251.
52. BI S, LADENHEIM EE, SCHWARTZ GJ, MORAN TH: A role for NPY overexpression in the dorsomedial hypothalamus in hyperphagia and obesity of OLETF rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001) 281(1):R254-R260.
53. KOJIMA M, HOSODA H, DATE Y et al.: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature (1999) 402(6762):656-660.
54. DATE Y, KOJIMA M, HOSODA H et al.: Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology (2000) 141(11):4255-4261.
55. TSCHOP M, SMILEY DL, HEIMAN ML: Ghrelin induces adiposity in rodents. Nature (2000) 407(6806):908-913.
56. CUMMINGS DE, PURNELL JQ, FRAYO RS, SCHMIDOVA K, WISSE BE, WEIGLE DS: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes (2001) 50(8):1714-1719.
57. CHEN HY, TRUMBAUER ME, CHEN AS et al.: Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology (2004) 145(6):2607-2612.
58. TOSHINAI K, DATE Y, MURAKAMI N et al.: Ghrelin-induced food intake is mediated via the orexin pathway. Endocrinology (2003) 144(4):1506-1512.
59. HEYMSFIELD SB, GREENBERG AS, FUJIOKA K et al. : Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA (1999) 282(16):1568-1575.
60. ROSENBAUM M, MURPHY EM, HEYMSFIELD SB, MATTHEWS DE, LEIBEL RL: Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J. Clin. Endocrinol. Metab. (2002) 87(5):2391-2394.
61. LAMBERT PD, ANDERSON KD, SLEEMAN MW et al.: Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc. Natl. Acad. Sci. USA (2001) 98(8):4652-6547.
62. BATTERHAM RL, COHEN MA, ELLIS SM et al.: Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. (2003) 349(10):94l-948.
63. VASTAG B: Experimental drugs take aim at obesity. JAMA (2003) 289:1763-1764.
64. CORPA ES, MCQUADE J, KRASNICKI S, CONZE DB: Feeding after fourth ventricular administration of neuropeptide Y receptor agonists in rats. Peptides (2001) 22(3):493-499.
65. ZHANG Y, MATHENY M, TUMER N, SCARPACE PJ: Aged-obese rats exhibit robust responses to a melanocortin agonist and antagonist despite leptin resistance. Neurobiol. Aging (2004) 25(10):1349-1360.
66. KIM YW, CHOI DW, PARK YH et al.: Leptin-like effects of MTII are augmented in MSG-obese rats. Regul. Pept. (2005) 127(1-3):63-70.
67. HOLLANDER P, MAGGS DG, RUGGLES JA et al.: Effect of pramlintide on weight in overweight and obese insulin-treated Type 2 diabetes patients. Obes. Res. (2004) 12(4):661-668.
68. RATNER RE, DICKEY R, FINEMAN M et al.: Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet. Med. (2004) 21(11):1204-1212.
69. MADSBAD S, SCHMITZ O, RANSTAM J, JAKOBSEN G, MATTHEWS DR; NN2211-1310 INTERNATIONAL STUDY GROUP: Improved glycemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care (2004) 27(6):1335-1342.
70. HARDER H, NIELSEN L, TU DT, ASTRUP A: The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care (2004) 27(8):1915-1921.
71. MCELROY SL, ARNOLD LM, SHAPIRA NA et al.: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160(2):255-261.
72. (Erratum in: Am. J. Psychiatry [2003] 160[3]:612)
73. WILDING J, VAN GAAL L, RISSANEN A, VERCRUYSSE F, FITCHET M; OBES-002 STUDY GROUP: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int. J. Obes. Relat. Metab. Disord. (2004) 28(11):1399-1410.
74. GADDE KM, FRANCISCY DM, WAGNER HR 2nd, KRISHNAN KR: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA (2003) 289(14):1820-1825.
75. GADDE KM, PARKER CB, MANER LG et al.: Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes. Res. (2001) 9(9):544-551.
76. ANDERSON JW, GREENWAY FL, FUJIOKA K, GADDE KM, MCKENNEYJ, O'NEIL PM: Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes. Res. (2002) 10(7):633-641.
77. JAIN AK, KAPLAN RA, GADDE KM et al.: Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes. Res. (2002) 10(10):1049-1056.
78. DE ZWAAN M, MITCHELL JE: Opiate antagonists and eating behavior in humans: a review. J. Clin. Pharmacol. (1992) 32:1060-1072.
79. STATNICK MA, TINSLEY FC, EASTWOOD BJ, SUTER TM, MITCH CH, HEIMAN ML: Peptides that regulate food intake: antagonism of opioid receptors reduces body fat in obese rats by decreasing food intake and stimulating lipid utilization. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2003) 284(6):R1399-R1408.
80. JEWETT DC, GRACE MK, JONES RM, BILLINGTON CJ, PORTOGHESE PS, LEVINE AS: The kappa-opioid antagonist GNTI reduces 050,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats. Brain Res. (2001) 909(1-2):75-80.
81. BAYS HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes. Res. (2004) 12:1197-1211. Comprehensive review of existing and investigational antiobesity biological targets and drugs.
82. ORTMANN S, KAMPE J, GOSSEL M et al.: The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats. Obes. Res. (2004) 12(8):1290-1297.